Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Novel farnesoid X receptor agonists described by Enanta Pharmaceuticals

April 25, 2018

FDA approves Jynarque to slow kidney function decline in adults with ADPKD

April 25, 2018

Reata offers update on ongoing CARDINAL study of bardoxolone in Alport syndrome

April 12, 2018

Recordati acquires rights to Cystagon

April 9, 2018

Topline results from phase II study of fostamatinib in IgA nephropathy

April 4, 2018

Retrophin initiates pivotal phase III DUPLEX study of sparsentan

April 4, 2018

Urovant initiates phase III trial of vibegron in overactive bladder

March 29, 2018

Vifor Pharma grants Zeria license to develop and market Veltassa in Japan

March 29, 2018

Bardoxolone methyl granted Sakigake designation in Japan

March 28, 2018

Vitaros end-of-review meeting scheduled by FDA

March 27, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis
BioWorld Science
Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of...